KalVista Pharmaceuticals, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 200 CROSSING BOULEVARD, FRAMINGHAM, MA, 01702
Mailing Address 200 CROSSING BOULEVARD, FRAMINGHAM, MA, 01702
Phone (857) 999-0075
Fiscal Year End 0430
EIN 200915291
Financial Overview
FY2025
$338.09M
Total Liabilities
$206.58M
Stockholders' Equity
$229.34M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
Insider Trading
STRONG SELL 6 insiders
16 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.